Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Return on Invested Capital (2021 - 2022)

Cartesian Therapeutics (RNAC) has disclosed Return on Invested Capital for 2 consecutive years, with 0.04% as the latest value for Q4 2022.

  • Quarterly Return on Invested Capital fell 409.0% to 0.04% in Q4 2022 from the year-ago period, while the trailing twelve-month figure was 0.04% through Dec 2022, down 409.0% year-over-year, with the annual reading at 2.01% for FY2025, 180.0% up from the prior year.
  • Return on Invested Capital for Q4 2022 was 0.04% at Cartesian Therapeutics, down from 0.13% in the prior quarter.
  • The five-year high for Return on Invested Capital was 4.13% in Q4 2021, with the low at 0.04% in Q4 2022.